EBITDA Margin % is calculated as EBITDA divided by its Revenue. Stoke Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-52.98 Mil. Stoke Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $6.23 Mil. Therefore, Stoke Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -850.52%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Stoke Therapeutics EBITDA Margin % Related Terms
Stoke Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STOK vs SION, RXRX, VRDN: EBITDA Margin % Comparison
For the Biotechnology subindustry, Stoke Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (STOK) has a EBITDA Margin % of -850.52% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stoke Therapeutics and its competitors. According to the industry distribution chart, Stoke Therapeutics ranks #690 out of 944 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Stoke Therapeutics' EBITDA Margin % too high?
Stoke Therapeutics' current EBITDA Margin % is -850.52%. Based on the distribution chart, Stoke Therapeutics ranks #690 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' EBITDA Margin % compare to SION and RXRX?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #690 out of 944 companies for EBITDA Margin %. This places Stoke Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Stoke Therapeutics and its competitors. Stoke Therapeutics's current EBITDA Margin % is -850.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.16, compared to a current price of $31.90 — trading 214% above its estimated fair value. The current EBITDA Margin % is -850.52%. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current EBITDA Margin % is -850.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $31.90 is trading 214% above its estimated GF Value™ of $10.16.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
EBITDA Margin %: -850.52%
GF Value™: $10.16 vs. price of $31.90 (214% above fair value)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score
Get the complete analysis for STOK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
